Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Signal peptide peptidase-like 2c impairs vesicular transport and cleaves SNARE proteins.
EMBO Rep. 20:e46451 (2019)
Verlagsversion
Preprint
DOI
PMC
Members of the GxGD-type intramembrane aspartyl proteases have emerged as key players not only in fundamental cellular processes such as B-cell development or protein glycosylation, but also in development of pathologies, such as Alzheimer's disease or hepatitis virus infections. However, one member of this protease family, signal peptide peptidase-like 2c (SPPL2c), remains orphan and its capability of proteolysis as well as its physiological function is still enigmatic. Here, we demonstrate that SPPL2c is catalytically active and identify a variety of SPPL2c candidate substrates using proteomics. The majority of the SPPL2c candidate substrates cluster to the biological process of vesicular trafficking. Analysis of selected SNARE proteins reveals proteolytic processing by SPPL2c that impairs vesicular transport and causes retention of cargo proteins in the endoplasmic reticulum. As a consequence, the integrity of subcellular compartments, in particular the Golgi, is disturbed. Together with a strikingly high physiological SPPL2c expression in testis, our data suggest involvement of SPPL2c in acrosome formation during spermatogenesis.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Snare ; Spp/sppl-family ; Glycosyltransferases ; Intramembrane Proteases ; Spermatogenesis; Requirements; Extraction; Expression; Proteases; Reveals; Binding; Er
ISSN (print) / ISBN
1469-221X
e-ISSN
1469-3178
Zeitschrift
EMBO Reports
Quellenangaben
Band: 20,
Heft: 3,
Artikelnummer: e46451
Verlag
EMBO Press
Verlagsort
111 River St, Hoboken 07030-5774, Nj Usa
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
CF Monoclonal Antibodies (CF-MAB)
Institute of Diabetes and Obesity (IDO)
Institute of Diabetes and Obesity (IDO)